Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of SGLT2 Inhibition on Albuminuria in Type 2 Diabetes
NCT04127084Phase 4Unknown
- Sponsor
- Xiamen University Zhongshan Hospital
- Start
- Oct 2019
- Primary completion
- Oct 2020
- Countries
- 1
01
Overview
Phase 4, open-label trial in type 2 diabetes mellitus (T2DM) and diabetic nephropathy (DN) (4 arms), sponsored by Xiamen University Zhongshan Hospital. Primary endpoints: Change in urinary albuminuria at 12 weeks, Change in estimated Glomerular Filtration Rate at 12 weeks and 6 more. Status: unknown.
02
Conditions
type 2 diabetes mellitus (T2DM)diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT04127084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04127084.